Practical Applications of Liquid Biopsy Across Multiple Tumor Types
Erica L. Carpenter, MBA, PhD, Director, Liquid Biopsy Laboratory; Research Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of Pennsylvania
During this presentation Dr. Carpenter will frame latest, mostly clinical applications, of liquid biopsy for multiple different solid tumor types within the context of the patient journey. She will look at liquid biopsy use for diagnosis, therapy selection, and disease surveillance and detection of minimal residual disease (MRD).
Early Detection of Cancer Using Cell-free DNA Fragmentomes
Victor Velculescu, MD, PhD, Professor of Oncology, Johns Hopkins University School of Medicine; Co-Director, Cancer Genetics and Epigenetics, Sidney Kimmel Cancer Center; Founder, Delfi Diagnostics
The presentation will be focused on a new generation of liquid biopsy approaches that provide high performing and cost effective analyses, allowing for tests for early detection and other cancer-related applications to be widely available in the US and around the world.
Navigating the Toughest Challenges of Immunotherapy with the EpiSwitch® CiRT
Steven Mamus, MD, Medical Director, Cancer Center of Sarasota-Manatee, Sarasota and Bradenton, Florida
Integrating Both Solid Tissue and Liquid Biopsy Strategies in Clinical Practice and Development
Nike Beaubier, MD, Senior Vice President, Life Science Pathology, Tempus Lab
This presentation will begin with an introduction in Tempus’ offerings including the 523 gene xF+ panel, and then explore the benefits of using concurrent solid tissue and liquid biopsy testing and longitudinal liquid biopsy testing in the clinic and how to integrate these strategies into clinical development.
Advances in Liquid Biopsy for Drug Development
David Fabrizio, MD, Vice President, Early Clinical Development, Foundation Medicine